Regeneron begins phase III trial of COVID-19 treatment in U.K.

By The Science Advisory Board staff writers

September 14, 2020 -- Regeneron Pharmaceuticals and the University of Oxford have commenced a phase III clinical trial of potential treatments for COVID-19.

The Recovery open-label study is one of the largest COVID-19 trials in the world, according to Regeneron. It will compare the effectiveness of Regeneron's REGN-COV2 antibody therapy to the standard of care in patients hospitalized with COVID-19.

REGN-COV2 is also being evaluated in two other phase II and phase III trials to treat COVID-19 and prevent COVID-19 transmission among household members, according to Regeneron.

Regeneron, Roche increase supply of COVID-19 antibody cocktail
Regeneron Pharmaceuticals and Roche are joining forces to develop, manufacture, and distribute Regn-COV2, Regeneron's investigational antiviral antibody...
BARDA awards supply contract to Regeneron for COVID-19 cocktail
Regeneron Pharmaceuticals was awarded a $450 million contract to manufacture and supply its REGN-COV2 antibody cocktail that is currently in phase...
Regeneron begins COVID-19 antibody treatment phase III trial
Regeneron Pharmaceuticals has begun adaptive late-stage phase III clinical trials evaluating its antibody cocktail, REGN-COV2, for the treatment and prevention...
Regeneron begins clinical trials for COVID-19 antibody treatment
Regeneron Pharmaceuticals has started its first clinical trial investigating an antibody treatment for COVID-19.
Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their existing collaboration to provide Regeneron with rights to develop in vivo CRISPR/Cas9-based...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
2020 ACCP Annual Meeting
September 20-22
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter